Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) represented a move of 0 percent or $-0.1 per share and closed its previous day trading session at $15.85. 669049 Shares were traded in the last trading session with an Average Volume of 506.37 Million Shares. The stock currently has a Market Capitalization of 697.24 Million.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
The stock traded between $11.90 and $18.99 over 1-Year time period showing its price to sales ratio of 4.38. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $5.61 and 200-Day Simple Moving Average of $2.61. Its Price to Free Cash Flow is 0 and Price to Book of 5.45.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) reported its Actual EPS of $-0.1/share. The analysts offering Earnings Estimates for the company were believing that Vanda Pharmaceuticals, Inc. could bring EPS of $-0.11/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 9.1 Percent.
Invitae Corporation (NYSE:NVTA)
In the last trading session, Invitae Corporation (NYSE:NVTA) added its value by 1.15% closing at the price of $6.16. The stock currently has market capitalization of 322.54 Million, with average volume of 693.27 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Invitae Corporation (NYSE:NVTA) is showing beta of 0. This particular value of beta suggests that Invitae Corporation (NYSE:NVTA) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Invitae Corporation (NYSE:NVTA) is at $-2.55.
The stock currently has RSI of 36.12. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.
Invitae Corporation (NYSE:NVTA) topped its 52-week high price of $10.41 on 04/03/17 and 52-Week Low Price of $ 3.80 on 02/13/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.47% and monthly volatility of 6.65% respectively.